0ND5.IL - H. Lundbeck A/S

IOB - IOB Delayed price. Currency in DKK

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
45 36 30 13 11

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees5,500

Key executives

NameTitlePayExercisedYear born
Dr. Deborah Dunsire M.D.Pres & CEO52.4MN/A1962
Mr. Jacob TolstrupExec. VP of Commercial Operations & Chief Commercial Officer6.5MN/A1972
Mr. Lars BangExec. VP of Product Devel. & Supply6.7MN/A1962
Dr. Per Johan LuthmanExec. VP of R&D6.6MN/A1959
Mr. Joerg HornsteinCFO & Exec. VP of Corp. FunctionsN/AN/A1977
Dr. Tarek Samad Ph.D.Sr. VP & Head of ResearchN/AN/AN/A
Mr. Palle Holm OlesenChief Specialist & VP of Investor RelationsN/AN/AN/A
Ms. Elise HaugeExec. VP of People & CommunicationN/AN/A1967
Mr. Ole ChrintzSr. VP of International MarketsN/AN/A1958
Mr. Keld Flintholm JorgensenExec. VP of Corp. Strategy & Bus. Devel.N/AN/A1971
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.


H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Corporate governance

H. Lundbeck A/S’s ISS governance QualityScore as of 1 June 2023 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.